Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Not signal
Semaglutide was originally approved by the Food and Drug Administration (FDA) to treat type 2 diabetes by lowering glucose levels in the body
Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight over 68 weeks, compared with 3.1% with placebo
Finally, 301 patients were analyzed (Figure 1)
This pricing transparency removes uncertainty and helps patients commit to long-term metabolic transformation without unexpected cost escalations
That requires longitudinal recordings the study did not provide
US$ 29.90
US$ 23.37
US$ 21.68
US$ 20.94
US$ 25.51
